Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Hepatitis C NS3 protease inhibition by peptidyl-alpha-ketoamide inhibitors: kinetic mechanism and structure.

Liu Y, Stoll VS, Richardson PL, Saldivar A, Klaus JL, Molla A, Kohlbrenner W, Kati WM.

Arch Biochem Biophys. 2004 Jan 15;421(2):207-16.

PMID:
14984200
2.

Cysteine protease activity is up-regulated in inflamed ankle joints of rats with adjuvant-induced arthritis and decreases with in vivo administration of a vinyl sulfone cysteine protease inhibitor.

Biroc SL, Gay S, Hummel K, Magill C, Palmer JT, Spencer DR, Sa S, Klaus JL, Michel BA, Rasnick D, Gay RE.

Arthritis Rheum. 2001 Mar;44(3):703-11.

3.

Fluorescent microplate assay for cancer cell-associated cathepsin B.

Hulkower KI, Butler CC, Linebaugh BE, Klaus JL, Keppler D, Giranda VL, Sloane BF.

Eur J Biochem. 2000 Jul;267(13):4165-70.

4.

Expression of human cathepsin K in Pichia pastoris and preliminary crystallographic studies of an inhibitor complex.

Linnevers CJ, McGrath ME, Armstrong R, Mistry FR, Barnes MG, Klaus JL, Palmer JT, Katz BA, Brömme D.

Protein Sci. 1997 Apr;6(4):919-21.

5.

Crystal structure of human cathepsin K complexed with a potent inhibitor.

McGrath ME, Klaus JL, Barnes MG, Brömme D.

Nat Struct Biol. 1997 Feb;4(2):105-9. No abstract available.

PMID:
9033587
6.

Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors.

Rosenthal PJ, Olson JE, Lee GK, Palmer JT, Klaus JL, Rasnick D.

Antimicrob Agents Chemother. 1996 Jul;40(7):1600-3.

8.

Vinyl sulfones as mechanism-based cysteine protease inhibitors.

Palmer JT, Rasnick D, Klaus JL, Brömme D.

J Med Chem. 1995 Aug 18;38(17):3193-6. No abstract available.

PMID:
7650671

Supplemental Content

Loading ...
Support Center